女性首发精神分裂症患者血清白细胞介素6水平与氯氮平用量及症状改善的关系(英文)  

Serum level of interleukin-6 associated with the dose of clozapine and amelioration of symptoms in female patients with first-episode schizophrenia

作　　者：徐建强[1] 吕路线[1] 石玉中[1] 

机构地区：[1]新乡医学院第二附属医院精神科,河南省精神病医院,河南省新乡市453002

出　　处：《中国组织工程研究与临床康复》2007年第30期6109-6112,共4页Journal of Clinical Rehabilitative Tissue Engineering Research

基　　金：河南省自然科学基金资助(0123030400);河南省教育厅科技攻关项目资助(2003320157)~~

摘　　要：背景:白细胞介素6是机体在免疫活动过程中产生的一种细胞因子。首发女性精神分裂症患者在服用氯氮平治疗后血清中白细胞介素6的变化是否为药物直接作用的结果及其是否与精神病症状的变化直接相关等问题尚需探讨。目的:观察女性首发精神分裂症患者血清白细胞介素6水平变化及其与氯氮平用量和症状改善的关系。设计:非随机同期病例-对照观察。单位:新乡医学院第二附属医院精神科。对象:于2005-05/12选取河南省精神病医院收治的精神分裂症女性患者20例为精神分裂症组。均符合中国精神障碍分类与诊断标准第3版精神分裂症的诊断标准;阳性症状与阴性症状量表评分>60分;未经治疗或门诊治疗至少2周未用药。排除有躯体疾病、内分泌及免疫系统疾病、营养不良及其他精神疾患,有过敏及激素治疗史,接受过免疫制剂治疗,近期内进行预防接种,怀孕或哺乳期妇女。对照组:同期选取年龄、性别与精神分裂症组差异无显著性意义的健康女性志愿者20例,排除标准同精神分裂症组。入组时均经受试者或监护人知情同意。方法:精神分裂症组患者均单一使用氯氮平,以25～50mg/d开始逐渐加量,3周内加到最大剂量,以最大疗效和最小副作用为用药原则。①采用酶联免疫吸附法测定精神分裂症组患者治疗前及治疗后第1,2,4周血清白细胞介素6水平。②采用高效液相色谱法测定氯氮平含量,以对照组受试者血清白细胞介素6水平作对照。③精神症状变化与白细胞介素6变化的相关分析:将患者治疗前、治疗后1,2,4周血清白细胞介素6水平分别与对应时段的阳性症状与阴性症状量表阳性症状分、阴性症状分、一般病理分、总分进行相关分析。主要观察指标:①氯氮平治疗前及治疗后各时间点患者血清白细胞介素6水平。②血清白细胞介素6水平与氯氮平含量的相关分析BACKGROUND： Interleukin-6 （IL-6） is a cytokine produced in the process of organic immune activities. The problems still need further exploration, including whether the changes of serum level of IL-6 after clozapine treatment ware induced directly by the drug, and whether IL-6 is directly correlated with the changes of the psychiatric symptoms in female patients.with first-episode schizophrenia.OBJECTIVE： To explore the changes of the serum level of IL-6 and its relation with the dose of clozapine and the amelioration of the symptoms in female patients with first-episode schizophrenia.DESIGN： A non-randomized case-control observation synchronically.SETTING： Department of Psychiatry, Second Affiliated Hospital of Xinxiang Medical College.PARTICIPANTS： Twenty female patients with first-episode schizophrenia （patient group） were selected from Henan Psychiatric Hospital. They all met the diagnostic standards of schizophrenia in the 3^rd edition of Chinese Classification and diagnostic criteria of Mental Disorders （CCMD-3）, their score of positive and negative syndrome scale （PANSS）was above 60 points, and had not been treated or at least not taking medicine for 2 weeks during clinical treatment.Patients with physical disease, endocrine and immune system diseases, malnutrition and other mental problems, those with the history of being allergic and hormone treatment, those receiving immune pharmaceutical treatment, and recently having been vaccinated preventively, and the pregnant and breast-feeding women were excluded. Twenty healthy female volunteers, who had no significnat difference in age and gender from the subjects in the patient group,were taken as the control group, and the exclusive standards were the same as those in the patient group. All the subjects were enrolled with the approval of themselves and their guardians.METHODS： All the patients were adminsitrated with clozapine only, with the dose being added by 25-50 mg per day,and the maximal dose was reached within 3 weeks. The pr

关 键 词：精神分裂症 氯氮平 白细胞介素6 

分 类 号：R749.3[医药卫生—神经病学与精神病学]